<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004102</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067321</org_study_id>
    <secondary_id>P30CA016087</secondary_id>
    <secondary_id>NYU-9863</secondary_id>
    <secondary_id>SANOFI-EFC7132</secondary_id>
    <secondary_id>NCI-G99-1593</secondary_id>
    <nct_id>NCT00004102</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer</brief_title>
  <official_title>A Phase II Trial of Eloxatin in Combination With 5-Fluorouracil and Leucovorin in Patients With Advanced Colorectal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells. Leucovorin&#xD;
      may increase the effectiveness of fluorouracil by making tumor cells more sensitive to the&#xD;
      drug.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy consisting of&#xD;
      oxaliplatin, fluorouracil, and leucovorin in treating patients who have colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Evaluate the quantitative and qualitative toxicities of oxaliplatin combined&#xD;
      with fluorouracil and leucovorin calcium in patients with advanced adenocarcinoma of the&#xD;
      colon or rectum.&#xD;
&#xD;
      OUTLINE: Patients receive leucovorin calcium IV over 10-20 minutes followed within 10 minutes&#xD;
      by fluorouracil IV bolus on days 1, 8, 15, 29, 36, and 43. Patients receive oxaliplatin IV&#xD;
      over 2 hours prior to leucovorin calcium and fluorouracil on days 1, 15, 29, and 43.&#xD;
      Treatment repeats every 8 weeks for 3 courses in the absence of disease progression or&#xD;
      unacceptable toxicity. Patients with stable or responding disease may receive additional&#xD;
      courses upon approval by the sponsor. Patients are followed at 30 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 18-35 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1999</start_date>
  <primary_completion_date type="Actual">November 2001</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX regimen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven advanced adenocarcinoma of the colon or&#xD;
        rectum No prior systemic chemotherapy OR Adjuvant chemotherapy only, completed 6 months&#xD;
        prior to study and with subsequent development of recurrent disease At least 1&#xD;
        bidimensionally measurable lesion No CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:&#xD;
        Greater than 12 weeks Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet&#xD;
        count at least 100,000/mm3 Hepatic: Bilirubin no greater than 2.0 mg/dL (no greater than&#xD;
        5.0 mg/dL if due to intrahepatic biliary obstruction not amenable to biliary decompression,&#xD;
        if approved by the protocol investigator) SGOT no greater than 4 times upper limit of&#xD;
        normal Renal: Creatinine no greater than 1.5 mg/dL Cardiovascular: No myocardial infarction&#xD;
        within the past 6 months No congestive heart failure Other: Not pregnant or nursing&#xD;
        Negative pregnancy test Fertile patients must use effective contraception No neurologic&#xD;
        disease No active or uncontrolled infection No other malignancy within the past 5 years&#xD;
        except nonmelanomatous skin cancer or carcinoma in situ of the cervix No medical or&#xD;
        psychiatric disorders that would prevent compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease&#xD;
        Characteristics Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy for&#xD;
        malignant disease Surgery: Recovered from any prior surgery Other: At least 30 days since&#xD;
        other prior investigational agent No other concurrent investigational agents No concurrent&#xD;
        anticancer agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard S. Hochster, MD</last_name>
    <role>Study Chair</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU School of Medicine's Kaplan Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hochster H, Chachoua A, Speyer J, Escalon J, Zeleniuch-Jacquotte A, Muggia F. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. J Clin Oncol. 2003 Jul 15;21(14):2703-7. doi: 10.1200/JCO.2003.02.071.</citation>
    <PMID>12860947</PMID>
  </results_reference>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>April 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2004</study_first_posted>
  <last_update_submitted>March 25, 2011</last_update_submitted>
  <last_update_submitted_qc>March 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2011</last_update_posted>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

